84
Participants
Start Date
February 28, 2020
Primary Completion Date
January 26, 2021
Study Completion Date
January 26, 2021
Interferon beta-1a
Interferon beta-1a 7.5 µg administered IM
Interferon beta-1a
Interferon beta-1a 15 µg administered IM
Interferon beta-1a
Interferon beta-1a 30 µg administered IM
Peginterferon beta-1a
Peginterferon beta-1a 31.25 µg administered SC
Peginterferon beta-1a
Peginterferon beta-1a 62.5 µg administered SC
Peginterferon beta-1a
Peginterferon beta-1a 125 µg administered SC
Placebo
Placebo (administered either IM or SC)
Spaulding Clinical Research, West Bend
Spaulding Clinical Research LLC
OTHER
Food and Drug Administration (FDA)
FED